Oklahoma Interventional Pain Management and Treatment Act; defining terms. Effective date.
SB 737 amends the Oklahoma Interventional Pain Management and Treatment Act by adding and clarifying definitions related to chronic pain treatment and interventional pain management. The bill defines “chronic pain,” “fluoroscope,” “interventional pain management,” and “supervision,” with the supervision definition requiring the supervising physician to be present in the office before, during, and after the procedure and to authorize and evaluate the procedure while maintaining the patient-physician relationship.
The bill also makes it unlawful to practice or offer interventional pain management in Oklahoma unless the person is licensed under the Oklahoma Allopathic Medical and Surgical Licensure and Supervision Act or the Oklahoma Osteopathic Medicine Act. At the same time, it preserves a limited role for certified registered nurse anesthetists (CRNAs), allowing them to administer lumbar inter-laminar epidural steroid injections or peripheral nerve blocks when requested by a physician and performed under physician supervision with timely on-site consultation available. It further prohibits CRNAs from operating a freestanding pain management facility without direct supervision by a physician board-certified in interventional pain management or an equivalent specialty.
The bill’s practical impact is to tighten the statutory framework governing who may provide interventional pain management services and under what supervision, while reinforcing physician oversight of pain clinics and procedures. It would affect physicians, osteopathic physicians, CRNAs, and pain management facilities by clarifying licensure and supervision requirements and by limiting independent operation of freestanding pain management practices by non-physicians.
There is little recorded public debate in the available materials, and no committee transcript or vote history is provided, so the overall sentiment cannot be measured from discussion. Based on the bill’s structure, it appears aimed at strengthening regulatory control and patient safety in pain management, while preserving some existing CRNA practice authority under physician supervision. The main point of potential contention is the balance between physician-led oversight and the scope of practice for CRNAs, especially regarding whether the supervision and facility restrictions are too restrictive or necessary to protect patients.
SB 737 would amend 59 O.S. 2021, Section 650, within the Oklahoma Interventional Pain Management and Treatment Act, by adding statutory definitions and tightening licensing and supervision requirements for interventional pain management. It would require practitioners offering interventional pain management to be licensed under the state’s allopathic or osteopathic medical licensure laws, while preserving limited CRNA authority for certain injections and blocks under physician supervision. It would also bar CRNAs from operating freestanding pain management facilities without direct supervision by a board-certified interventional pain management physician or equivalent, thereby affecting medical licensing, pain clinics, and scope-of-practice rules in Oklahoma.
No committee transcripts or votes are available, and the bill’s last recorded action was a second reading referral to Health and Human Services. As a result, there is no documented public sentiment in the provided record. The bill’s text suggests a policy preference for stronger physician oversight and tighter regulation of pain management procedures, which may be viewed favorably by proponents of patient safety and professional standards, but potentially unfavorably by those concerned about limits on CRNA autonomy and access to pain treatment services.
The likely area of contention is the scope of practice for certified registered nurse anesthetists versus physician control of interventional pain management. Supporters would likely argue that the bill protects patients by ensuring direct physician supervision and limiting independent operation of pain facilities, while opponents may argue that the restrictions are overly broad, reduce flexibility in pain care delivery, and constrain CRNAs who already perform certain procedures under existing supervision rules. Another possible point of debate is whether the bill’s definition of supervision is too rigid because it requires the physician to be present in the office before, during, and after the procedure.